Cardea Bio Appoints Genomics Industry Veteran Dawn Barry to Its Board of Directors
Cardea technology taps into biology's internal communication to expand or replace current optical and static measurements with interactive live streams of multi-omic signals and analyses. Graphene, a biocompatible nanomaterial, is a near perfect conductor as it is only one atom thick, and Cardea has patented uses of this material to gain a signal resolution high enough to listen into real-time molecular interactions.
"Having experienced the thrill of the Human Genome Project and all the subsequent innovations within genomics and diagnostics, I'm excited to join Cardea's board of directors to help enable the next phase of biomolecular data: real-time multi-omics," says Dawn Barry and continues, "I look forward to working with the board to advance groundbreaking innovations and take our understanding of biology to the next level."
Barry was an early employee of Genaissance Pharmaceuticals, one of the first genomics startups focused on individualized medicine and DNA-based diagnostic testing in the late 1990s. She then spent 12 years helping build Illumina, where she ultimately served as the Vice President of Applied Genomics and led pioneering teams in precision medicine, translational genomics, population genomics, and clinical screening applications, among others. Barry was a 2016 TEDx San Diego speaker, San Diego Business Journal’s Business Woman of the Year in 2017 and a Girl Scouts San Diego Cool Women recipient in 2019, and she serves on the Board of the Alzheimer’s Association San Diego/Imperial County Chapter. Her current company, LunaPBC, has received numerous awards from notable institutions including the Word Economic Forum and Fast Company.
“We are very pleased to welcome Dawn Barry to our board and we look forward to leveraging her talent, expertise, and veteran experience in the genomics industry,” states Michael Heltzen, CEO at Cardea Bio. He added, “we value the perspectives and passion that she brings to our board as we plan for rapid growth in all areas of our business.”
Spearheading a new class of life science signal detection technology, Cardea’s proprietary Cardean Transistors™ employ graphene to link the digital world of semiconductor microelectronics directly to molecular biology, thereby enabling the development of a new generation of highly sensitive diagnostics, research tools, and other biosensor-integrated applications for a myriad of industries.
About Cardea Bio
Cardea has linked computers to the live molecular signals running biology. Its multi-omics technology consists of a Tech+Bio Infrastructure (hardware, software and wetware) and Chipsets manufactured with proprietary graphene-based, biology-gated transistors, called Cardean Transistors™.
Cardean Transistors leverage graphene, a nanomaterial that is biocompatible and a near perfect conductor as it is only one atom thick, in contrast to the common semiconductor material, silicon. Cardea thereby gains a signal resolution high enough to listen into molecular signals in a manner that replaces optical and static measurements with interactive live-streams of multi-omic signals and analyses.
Cardea is on a long-term mission they call “Linking up to Life” to empower its partners with Tech+Bio solutions that make significant positive impacts on the world via innovative applications that are “Powered by Cardea.” For more information about Cardea Bio Inc. visit www.cardeabio.com.
Investor Relations and Media Inquiries
Chief Business Officer
Source: Cardea Bio